(Q54468632)

English

Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23127227

Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway. (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23127227

steatohepatitis

0 references

non-alcoholic steatohepatitis

1 reference

based on heuristic

inferred from title

author name string

Wei Zhang

1

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23127227

Rong Wu

2

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23127227

Feng Zhang

3

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23127227

Yizhi Xu

4

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23127227

Bo Liu

5

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23127227

Yingying Yang

6

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23127227

Huamei Zhou

7

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23127227

Lulu Wang

8

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23127227

Keqiang Wan

9

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23127227

Xiaoqiu Xiao

10

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23127227

Xia Zhang

11

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23127227

publication date

1 December 2012

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23127227

Clinical and Experimental Pharmacology and Physiology

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23127227

39

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23127227

12

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23127227

1026-1033

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23127227

The natural history of non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

Recent concepts in non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

The potential role of leptin and adiponectin in obesity: a comparative review

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

Insulin-sensitizing properties of adiponectin

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

Adiponectin activation of AMPK disrupts leptin-mediated hepatic fibrosis via suppressors of cytokine signaling (SOCS-3)

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

Prevention of steatohepatitis by pioglitazone: implication of adiponectin-dependent inhibition of SREBP-1c and inflammation

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

The effect of pioglitazone on the liver: role of adiponectin.

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

Histological grading and staging of chronic hepatitis

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

Steatohepatitis: a tale of two "hits"?

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

Hepatic stellate cells: a target for the treatment of liver fibrosis

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content

1 reference

https://api.crossref.org/works/10.1111%2F1440-1681.12020

21 January 2018

Identifiers

10.1111/1440-1681.12020

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23127227

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 May 2018

http://europepmc.org/abstract/MED/23127227

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54468632&oldid=1988620026"